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Background: Mucosal melanomas represent about 1% of all melanoma cases and classically have a worse
prognosis than cutaneous melanomas. Due to the rarity of mucosal melanomas, only limited clinical studies with
metastatic mucosal melanoma are available. Mucosal melanomas most commonly contain mutations in the gene
CKIT, and treatments have been investigated using targeted therapy for this gene. Mutations in mucosal melanoma
are less common than in cutaneous or uveal melanomas and occur in descending order of frequency as: CKIT (20%),
NRAS (5%) or BRAF (3%). Mutations in G-alpha proteins, which are associated with activation of the mitogen-activated
protein kinase pathway, have not been reported in mucosal melanomas. These G-alpha protein mutations occur
in the genes GNAQ and GNA11 and are seen at a high frequency in uveal melanomas, those melanomas that
begin in the eye.
Case presentation: A 59-year old Caucasian male was diagnosed with a mucosal melanoma after evaluation for
what was thought to be a hemorrhoid. Molecular analysis of the tumor revealed a GNAQ mutation. Ophthalmologic
exam did not disclose a uveal melanoma.
Conclusion: Here we report, to our knowledge, the first known case of GNAQ mutation in a patient with metastatic
mucosal melanoma.
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The incidence and the mortality of melanoma have in-
creased over the last several decades with more than 76,000
estimated new cases and more than 9,000 estimated deaths
in the USA in 2013 [1]. Although most of melanoma is
cutaneous in origin, it can arise from extra-cutaneous sites
such as the uveal tract and mucosal surfaces where mela-
nocytes exist. The mucosal origin melanomas which
mostly arise from the mucosal membrane of the head and
neck, the anorectal mucosa and the vulvovaginal mucosa
have distinct biologic and clinical features compared with
cutaneous melanomas. Mucosal melanomas are rare but
very aggressive. The rate of mucosal melanoma is 2.2
cases per million per year, and the five-year survival is a
mere 25% compared to over 200 cases per million and
over 80% five-year survival for cutaneous melanoma [2,3].
The poor prognosis is likely due to the obscured anatomic* Correspondence: sppatel@mdanderson.org
2Department of Melanoma Medical Oncology, University of Texas MD
Anderson Cancer Center, Houston, TX, USA
Full list of author information is available at the end of the article
© 2014 Kim et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.sites and the rich lymphovascular supply of the mucosa
[2]. Although the discovery of BRAF gene mutation and
the advancement of immunotherapy in melanoma have
led to the development of highly effective targeted therapy
such as vemurafenib, dabrafenib, and trametinib and dur-
able immunotherapy such as interleukin-2 and ipilimumab,
the efficacy of these treatments in metastatic mucosal mel-
anoma is not clear due to limited number of these patients
included in clinical trials. Recently, several clinical trials re-
ported promising results with targeting of CKIT mutation
in mucosal melanoma [4-6]. CKIT mutations are reported
in 21% of mucosal melanoma, and only patients with mu-
cosal melanoma harboring a special subset of CKIT muta-
tions such as L576P and K642E in exon 11 and 13 may
have a clinical benefit from c-KIT inhibitors [7]. The role
of amplification of CKIT and response to c-KIT inhibitors
has also been studied [6,8]. Despite these advances, further
workup is necessary to define the standard of care for mu-
cosal melanoma.
GNAQ and GNA11 are alpha subunits of heterotrimeric
G proteins, which couple seven transmembrane domain. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 The melanoma cells displayed diffuse clear cell
change and intracytoplasmic melanin pigment (H & E, 10×).
Kim et al. BMC Cancer 2014, 14:516 Page 2 of 4
http://www.biomedcentral.com/1471-2407/14/516receptors to intracellular signaling pathways [9]. Mutations
in the genes GNAQ and GNA11 are critical for develop-
ment and progression of uveal melanoma and are associ-
ated with activation of the mitogen-activated protein kinase
(MAPK) pathway [10,11]. This same pathway is activated
by oncogenic BRAF mutations in cutaneous melanoma
[12]. Approximately, 80% of primary uveal melanomas have
GNAQ or GNA11 mutations. However, GNAQ or GNA11
mutations have not been reported in mucosal melanoma.
Here, we present a patient with metastatic mucosal mel-
anoma harboring a classic GNAQ mutation.
Case presentation
A 59-year-old otherwise healthy Caucasian man was diag-
nosed with a mucosal melanoma during hemorrhoid evalu-
ation in August of 2009. Histopathological examination
revealed a polypoid tumor occupying lamina propria and
submucosa of the anal canal with intraepithelial lentiginous
component in the center of the lesion. The tumor cells
were epithelioid and showed clear cell change. Immunohis-
tochemical studies showed the tumor cells to be positive
for S100 and Melan-A. A diagnosis of a 15-mm thick
mucosal melanoma with ulceration, 6 mitotic figures
per mm2 and perineural invasion in the anal canal was
made (Figures 1, 2 and 3). Molecular analysis showed
the melanoma harbored a GNAQ mutation with wild-type
BRAF, KIT and NRAS genes. The GNAQ gene mutationFigure 1 Histolological appearance of the anal melanoma.
A bulky, polypoid mass predominantly involving lamina propria
and submucosa was seen. The tumor showed focal intraepithelial
lentiginous component, best interpreted as melanoma in situ
(H & E, 4×).
Figure 3 An immunohistochemical study for MART-1
highlighted the invasive and intraepithelial components of
the lesion, supporting a diagnosis of mucosal melanoma
(immunohistochemical study, 4×).
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in codon 209 (Q209P) which has been reported in uveal
melanoma at a frequency of 20.8% but not in cutaneous
melanoma or other subtypes of the disease [10,13].
The patient underwent a wide local excision of the pri-
mary melanoma with subsequent adjuvant radiation ther-
apy. He was without relapse until January of 2010, when
he had locally recurrent disease for which he underwent
another wide local excision. He again remained free of dis-
ease until July of 2010 when he was found to have meta-
static lesions in the perinephric lymph nodes, the liver,
and lung, for which he received 2 doses of ipilimumab
(3 mg/kg intravenous Day 1) and temozolomide (200 mg/m2
by mouth Days 1–4) [14] with further disease progression
and new metastatic lesions in hilar and mediastinal lymph
nodes and in the right adrenal gland. Subsequently, he re-
ceived two cycles of the combination of carboplatin, pacli-
taxel and bevacizumab before he had further disease
progression in January of 2011. He started imatinib at
400 mg twice a day in February of 2011. Due to further
disease progression with imatinib, ipilimumab (3 mg/kg)
was re-introduced in April of 2011 and he completed 4 cy-
cles of ipilimumab. However, his disease progressed fur-
ther with multiple metastatic lesions and he expired in
August of 2011.
Conclusions
GNAQ and GNA11 mutations, which are potential drivers
of MAPK activation, have been reported in blue nevi and
in up to 85% of cases of uveal melanoma [10,11,15]. Mu-
tations occur in a mutually exclusive fashion and affect
codons 209 (95%) and 183 (5%) in both genes. Although
GNAQ and GNA11 mutations have been reported in a
cutaneous melanoma case and a cell line from cutane-
ous melanoma [10,16], there are no data to demonstrate
GNAQ or GNA11 mutations in mucosal melanoma. It is
possible that our patient may have had an undetected or
spontaneously regressed primary uveal melanoma since
his melanoma harbored the GNAQ mutation and me-
tastasized to liver which is the most common metastatic
site of uveal melanoma [17]. However, spontaneous re-
gression of primary uveal melanoma is extremely rare in
comparison to cutaneous melanoma [18]; furthermore,
anal canal is not a common metastatic site as a single
and the first metastatic lesion of uveal melanoma [17],
and our patient did not have any evidence of uveal mel-
anoma in multiple magnetic resonance image (MRI) of
the brain. In addition, he had had frequent ophthalmol-
ogy exams with his retina specialist due to multiple ret-
inal detachments 3 years before he was diagnosed with
melanoma. These follow-ups included slit-lamp exami-
nations. Another possible explanation is that our patient
might have an undetected or regressed primary cutaneous
melanoma, since GNAQ mutation has been reported inone case of cutaneous melanoma [9]. However, it is less
likely since our patient did not have any suspected cutane-
ous lesions during multiple thorough and detailed clinical
examinations, and the predominant metastatic site of mel-
anoma in the gastrointestinal tract is not the anal canal
but the small bowel [19]. The melanoma seen in the anal
canal, although predominantly involving lamina propria
and submucosa, was interpreted to be most likely primary
due to presence of intraepidermal (in situ) melanoma
showing lentiginous pattern of growth (as mucosal melan-
oma frequently does), along with the lack of clinical evi-
dence of tumor elsewhere at the time of diagnosis. Since
GNAQ mutations are potential drivers of MAPK activa-
tion similar to oncogenic BRAF, and a recent clinical study
demonstrated a significant clinical benefit of selumetinib
(a selective MEK inhibitor) in metastatic uveal melanoma
with GNAQ or GNA11 mutations [20], our patient might
have achieved clinical response with selumetinib. Unfortu-
nately, he did not receive a MEK inhibitor as part of his
treatment course.
To our knowledge, this is the first case report to demon-
strate mucosal melanoma harboring a GNAQ mutation.
This case suggests that molecular profiling may give us
better understanding of genetic changes in mucosal mel-
anoma and may afford actionable targets for therapy.
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